U.S. Markets closed

Pfizer doesn't deserve any credit for 'rolling back' its price increases at Trump's demand. Here's why

Los Angeles Times
Pfizer doesn't deserve any credit for 'rolling back' its price increases at Trump's demand. Here's why

The “blueprint” mentioned in the announcement is the policy statement Trump issued May 11, setting forth several initiatives and proposals for bringing drug prices down. Most experts in the field faulted the blueprint for neglecting some of the most potentially effective options. Pharmaceutical stocks